232
Participants
Start Date
July 13, 2021
Primary Completion Date
September 21, 2022
Study Completion Date
September 21, 2022
Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
Center for Tobacco Research and Intervention, Madison
University of Wisconsin, Madison
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH